IL296823A - Substituted 3-phenoxyazetidin-1-yl-pyrazines having gpr52 agonistic activity - Google Patents

Substituted 3-phenoxyazetidin-1-yl-pyrazines having gpr52 agonistic activity

Info

Publication number
IL296823A
IL296823A IL296823A IL29682322A IL296823A IL 296823 A IL296823 A IL 296823A IL 296823 A IL296823 A IL 296823A IL 29682322 A IL29682322 A IL 29682322A IL 296823 A IL296823 A IL 296823A
Authority
IL
Israel
Prior art keywords
dynamicpdf
pmol
mixture
unlicensed
evaluating
Prior art date
Application number
IL296823A
Other languages
English (en)
Hebrew (he)
Original Assignee
Boehringer Ingelheim Int
Arena Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int, Arena Pharm Inc filed Critical Boehringer Ingelheim Int
Publication of IL296823A publication Critical patent/IL296823A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL296823A 2020-03-30 2021-03-29 Substituted 3-phenoxyazetidin-1-yl-pyrazines having gpr52 agonistic activity IL296823A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063001640P 2020-03-30 2020-03-30
PCT/EP2021/058099 WO2021198149A1 (en) 2020-03-30 2021-03-29 Substituted 3-phenoxyazetidin-1-yl-pyrazines having gpr52 agonistic activity

Publications (1)

Publication Number Publication Date
IL296823A true IL296823A (en) 2022-11-01

Family

ID=75362607

Family Applications (1)

Application Number Title Priority Date Filing Date
IL296823A IL296823A (en) 2020-03-30 2021-03-29 Substituted 3-phenoxyazetidin-1-yl-pyrazines having gpr52 agonistic activity

Country Status (20)

Country Link
US (1) US11780827B2 (cg-RX-API-DMAC7.html)
EP (1) EP4126850B1 (cg-RX-API-DMAC7.html)
JP (1) JP7617134B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220161454A (cg-RX-API-DMAC7.html)
CN (1) CN115697997B (cg-RX-API-DMAC7.html)
AR (1) AR121675A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021250303A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022018996A2 (cg-RX-API-DMAC7.html)
CA (1) CA3176265A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022014886A2 (cg-RX-API-DMAC7.html)
CR (1) CR20220554A (cg-RX-API-DMAC7.html)
DO (1) DOP2022000203A (cg-RX-API-DMAC7.html)
EC (1) ECSP22080683A (cg-RX-API-DMAC7.html)
IL (1) IL296823A (cg-RX-API-DMAC7.html)
JO (1) JOP20220235A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022012067A (cg-RX-API-DMAC7.html)
PE (1) PE20221918A1 (cg-RX-API-DMAC7.html)
PH (1) PH12022552553A1 (cg-RX-API-DMAC7.html)
TW (1) TW202204343A (cg-RX-API-DMAC7.html)
WO (1) WO2021198149A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4139284A1 (en) 2020-04-22 2023-03-01 Neurocrine Biosciences, Inc. Gpr52 modulators and methods of use
WO2023041432A1 (en) 2021-09-14 2023-03-23 Boehringer Ingelheim International Gmbh 3-phenoxyazetidin-1-yl-heteroaryl pyrrolidine derivatives and the use thereof as medicament
CN119143731B (zh) * 2024-09-13 2025-08-26 中国海洋大学 一种吡嗪酰胺类化合物及其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2361149A1 (en) 1998-12-23 2000-07-06 Eli Lilly And Company Aromatic amides
JPWO2009107391A1 (ja) 2008-02-27 2011-06-30 武田薬品工業株式会社 6員芳香環含有化合物
GB0808668D0 (en) * 2008-05-13 2008-06-18 Univ Aberdeen Materials and methods relating to a G-protein coupled receptor
EP2298731A4 (en) 2008-06-25 2011-09-21 Takeda Pharmaceutical AMIDE COMPOUND
EP2518054A1 (en) * 2009-12-24 2012-10-31 Takeda Pharmaceutical Company Limited Amide compound
EP2530078A1 (en) 2010-01-27 2012-12-05 Takeda Pharmaceutical Company Limited Thiazole derivative
WO2011145735A1 (ja) 2010-05-21 2011-11-24 武田薬品工業株式会社 チアゾール誘導体
WO2012020738A1 (ja) 2010-08-09 2012-02-16 武田薬品工業株式会社 複素環化合物およびその用途
WO2012076063A1 (en) 2010-12-10 2012-06-14 Rottapharm S.P.A. Pyridine amide derivatives as ep4 receptor antagonists
MX373876B (es) * 2015-04-29 2020-03-26 Arena Pharm Inc 1-heteroaril-indolin-4-carboxamidas como moduladores de gpr52 útiles para el tratamiento o prevención de trastornos relacionados a las mismas.
AU2016324317A1 (en) * 2015-09-17 2018-03-08 Coda Biotherapeutics, Inc. Compositions and methods for treating neurological disorders

Also Published As

Publication number Publication date
AU2021250303A1 (en) 2022-09-22
US11780827B2 (en) 2023-10-10
JOP20220235A1 (ar) 2022-09-28
MX2022012067A (es) 2022-10-13
DOP2022000203A (es) 2022-11-30
ECSP22080683A (es) 2022-11-30
CA3176265A1 (en) 2021-10-07
TW202204343A (zh) 2022-02-01
CO2022014886A2 (es) 2022-10-31
PE20221918A1 (es) 2022-12-29
KR20220161454A (ko) 2022-12-06
JP2023522307A (ja) 2023-05-30
BR112022018996A2 (pt) 2022-11-01
WO2021198149A1 (en) 2021-10-07
CN115697997B (zh) 2024-07-30
EP4126850B1 (en) 2024-04-17
AR121675A1 (es) 2022-06-29
EP4126850A1 (en) 2023-02-08
US20220356172A1 (en) 2022-11-10
CR20220554A (es) 2023-01-09
CN115697997A (zh) 2023-02-03
PH12022552553A1 (en) 2024-01-03
JP7617134B2 (ja) 2025-01-17

Similar Documents

Publication Publication Date Title
US12012373B2 (en) Cannabinoid derivatives
JP6483156B2 (ja) 糖尿病などの疾患の治療用のピロリジンgpr40モジュレータ
EP4126850B1 (en) Substituted 3-phenoxyazetidin-1-yl-pyrazines having gpr52 agonistic activity
JP2010524940A (ja) ピリミジノン誘導体およびそれらの使用方法
JP2019504836A (ja) アンドロゲン受容体アンタゴニストとしての置換チオヒダントイン誘導体
JP2012509911A (ja) 新規の化合物
JP2012509910A (ja) 新規の化合物
KR101567116B1 (ko) Nk1 수용체 길항제로서의 5-[5-[2-(3,5-비스(트리플루오로메틸)페닐)-2-메틸프로파노일메틸아미노]-4-(4-플루오로-2-메틸페닐)]-2-피리디닐-2-알킬-프롤린아미드
EP4402138B1 (en) 3-phenoxyazetidin-1-yl-heteroaryl pyrrolidine derivatives and the use thereof as medicament
JP6488320B2 (ja) 糖尿病などの疾患の治療用のピロリジンgpr40モジュレータ
EP2266976B1 (en) Fused ring thrombin receptor antagonists
US20090029979A1 (en) 5-htx modulators
JP2021042231A (ja) 中枢神経系に関連している疾患または病態の治療に有用であるn−(ヘテロ)アリール置換複素環誘導体
US20190062305A1 (en) Pyridyl or pyrazinyl compounds carrying a methyl-bound alpha-amino acid amide group
WO2006115134A1 (ja) 新規なベンゾフラン誘導体、それを含有する医薬組成物およびそれらの用途
HK1241366A1 (en) Pyrrolopyrimidine derivatives as nr2b nmda receptor antagonists